

Customer No. 20350  
TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
(415) 576-0200

ASSISTANT COMMISSIONER FOR PATENTS  
BOX PATENT APPLICATION  
Washington, D.C. 20231

Sir:

Transmitted herewith for filing under 37 CFR 1.53(b) is the

- ☒ patent application of  
☐ continuation patent application of  
☐ divisional patent application of  
☐ continuation-in-part patent application of

Inventor(s)/Applicant Identifier: Maw Shenq CHERN and Pamela RONALD

For: PROTEINS THAT REGULATE SYSTEMIC ACQUIRED RESISTANCE IN PLANTS

☐ This application claims priority from each of the following Application Nos./filing dates:

the disclosure(s) of which is (are) incorporated by reference.

☐ Please amend this application by adding the following before the first sentence: "This application is a ☐ continuation ☐ continuation-in-part of and claims the benefit of U.S. Provisional Application No. 60/\_\_\_\_\_, filed \_\_\_\_\_, the disclosure of which is incorporated by reference."

Enclosed are:

- ☒ 35 page(s) of specification  
☒ 7 page(s) of claims  
☒ 1 page(s) of Abstract  
☐ \_\_\_\_\_ sheet(s) of ☐ formal ☐ informal drawing(s).  
☐ An assignment of the invention to \_\_\_\_\_  
☐ A ☐ signed ☐ unsigned Declaration & Power of Attorney  
☒ A ☐ signed ☒ unsigned Declaration.  
☐ A Power of Attorney.  
☐ A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27 ☐ is enclosed ☐ was filed in the prior application and small entity status is still proper and desired.  
☐ A certified copy of a \_\_\_\_\_ application.  
☐ Information Disclosure Statement under 37 CFR 1.97.  
☐ A petition to extend time to respond in the parent application.  
☐ Notification of change of ☐ power of attorney ☐ correspondence address filed in prior application.

**In view of the Unsigned Declaration as filed with this application and pursuant to 37 CFR §1.53(f),  
Applicant requests deferral of the filing fee until submission of the Missing Parts of Application.**

DO NOT CHARGE THE FILING FEE AT THIS TIME.

Telephone:  
(415) 576-0200

Facsimile:  
(415) 576-0300

Kevin Bastian  
Reg No.: 34,774  
Attorneys for Applicant

**PATENT APPLICATION**

**Proteins that Regulate Systemic Acquired Resistance in Plants**

Inventor(s):

Maw Shenq Chern

Pamela Ronald

Assignee: The Regents of the University of California  
300 Lakeside Drive, Oakland, California 94612-3558

Entity:

## CROSS-REFERENCES TO RELATED APPLICATIONS

The application is related to the application filed on March 11, 1999,

5     Attorney Docket No. 02307O-092500.

## BACKGROUND OF THE INVENTION

Plant pathogens cause hundreds of millions of dollars in damage to crops in the United States annually and cause significantly more damage worldwide.

10     Traditional plant breeding techniques have developed some plants that resist specific pathogens, but these techniques are limited to genetic transfer within breeding species and can be plagued with the difficulty of introducing non-agronomic traits that are linked to pathogen resistance. Furthermore, traditional breeding has focused on resistance to specific pathogens rather than general, or systemic, resistance to a wide spectrum of  
15     pathogens.

One of the most important crop plants in the world is rice. Little is currently known about the mechanisms by which rice resists pathogens. Therefore, an important goal in agriculture is to identify genetic components that enable plants in general, and rice in particular, to resist pathogens, thereby allowing for the development  
20     of systemically resistant plants through biotechnology.

Systemic acquired resistance (SAR) is a general plant resistance response that can be induced during a local infection by an avirulent pathogen. While early studies of SAR were conducted using tobacco mosaic virus (TMV) and its Solanaceous hosts (see, *e.g.*, Ross, A.F. *Virology* 14: 340-358 (1961)), SAR has been demonstrated in many  
25     plant species and shown to be effective against not only viruses, but also bacterial and fungal pathogens (see, *e.g.*, Kuc, J. *Bioscience* 32:854-860 (1982) and Ryals, *et al.* *Plant Cell* 8:1809-1819 (1996)). A necessary signal for SAR induction is salicylic acid (SA); plants that fail to accumulate SA due to the expression of an SA-oxidizing enzyme salicylate hydroxylase are impaired in SAR (Gaffney, T., *et al.* *Science* 261:754-756  
30     (1993)). Conversely, an elevation in the endogenous level of SA or exogenous application of SA or its synthetic analogs, such as 2,6-dichloroisonicotinic acid (INA), not only results in an enhanced, broad-spectrum resistance but also stimulates concerted expression of a battery of genes known as pathogenesis-related (*PR*) genes (see, *e.g.*,

Malamy, J., *et al. Science* 250:1002-1004 (1990); Métraux, J.-P., *et al. Science* 250:1004-1006 (1990); Rasmussen, J. B., *et al. Plant Physiol* 97:1342-1347 (1991); Yalpani, N., *et al. Plant Cell* 3:809-818 (1991); White, R. F. *Virology* 99:410-412 (1979); Métraux, J.-P., *et al.* (1991) In *Advances in Molecular Genetics of Plant-Microbe Interactions*, eds.

- 5 Hennecke, H. & Verma, D. P. S. (Kluwer Academic, Dordrecht, The Netherlands), Vol. 1, pp. 432-439; Ward *et al. Plant Cell* 3:1085-1094 (1991); and Uknes *et al. Plant Cell* 4:645-656 (1992)). *PR* genes may play direct roles in conferring resistance because their expression coincides with the onset of SAR and some of the *PR* genes encode enzymes with antimicrobial activities (see, *e.g.*, Ward *et al. Plant Cell* 3:1085-1094 (1991); and
- 10 Uknes *et al. Plant Cell* 4:645-656 (1992)). Therefore, understanding the regulation of *PR* gene expression has been a focal point of research in plant disease resistance.

The *Arabidopsis* gene NPR1 (Cao *et al.*, *Plant Cell* 88(1):57-63 (1997) has been shown to be a key component of SA-regulated *PR* gene expression and disease resistance because *npr1* mutants fail to express *PR1*, *PR2*, and *PR5* and display enhanced

15 susceptibility to infection even after treatment with SA or INA. Furthermore, transgenic plants overexpressing NPR1 display a more dramatic induction of *PR* genes during an infection and show complete resistance to *Pseudomonas syringae* pv. *maculicola* 4326 and *Peronospora parasitica* Noco, two very different pathogens that are virulent on wild-type *A. thaliana* plants (Cao, H., *et al. Proc. Natl. Acad. Sci. USA* 95:6531-6536 (1998)).

20 NPR1 contains at least four ankyrin repeats, which are found in proteins with very diverse biological functions and are involved in protein-protein interactions (Bork, P. (1993) *Proteins: Structure, Function, and Genetics* 17, 363-374. Michaely, P., and Bennet, V. (1992) *Trends in Cell Biology* 2:127-129.). The functional importance of the ankyrin repeat domain has been demonstrated by mutations found in the *npr1-1* and

25 the *nim1-2* alleles where the highly conserved histidine residues in the third and the second ankyrin repeats, respectively, are changed to a tyrosine. Because these conserved histidine residues are involved in the formation of hydrogen bonds which are crucial in stabilizing the three dimensional structure of the ankyrin-repeat domain (Gorina, S. & Pavletich, N.P. *Science* 274, 1001-1005 (1996)), *npr1-1* and *nim1-2* mutations may cause

30 disruption in the local structure within the ankyrin-repeat domain and abolish its ability to interact with other proteins. These data suggest that NPR1 may exert its regulatory function by interacting with other proteins.

bZIP proteins are one class of proteins that interact with NPR1 in a yeast two-hybrid system. bZIP proteins are transcription factors that have highly conserved

DNA binding domains. Although functions have been postulated for some plant bZIP gene products (see, e.g., Kawata, T., *et al. Nucleic Acids Res.* 20, 1141 (1992); Xiang, C., *et al. Plant Mol. Biol.* 34, 403-415 (1997); Zhang, B., *et al. Plant J.* 4, 711-716 (1993); Schindler, U., *et al.*, A. R. *Plant Cell* 4, 1309-1319 (1992); Miao, Z. H., *et al. Plant Mol. Biol.* 25, 1-11 (1994); and Lam, E. & Lam, Y.K.-P. *Nucleic Acids Res.* 23, 3778-3785 (1995); Foley *et al.*, *Plant J.* 3(5):669-79 (1993); Fromm, *et al.*, *Mol. Gen. Genet.* 229:181-88 (1991); 1998 review, Schwechheimer and Bevan, *Trends in Plant Science*, 3:378 (1998); and Katagiri *et al.*, *Nature* 340:727-30 (1989)), little is known about the regulation of bZIP gene products and there are no reports of their interaction with proteins associated with plant disease resistance, other than NPR1.

In spite of recent research of the genetic control of plant resistance to pathogens, little progress has been reported in the identification and analysis of gene products interacting with key regulators of pathogen resistance such as *NPR1*. Furthermore, most research has been carried out in model plant systems such as *Arabidopsis*. Little research has been performed on crop plants such as rice. Identification and characterization of rice NPR1 orthologs as well as rice gene products that interact with NPR1 or bZIP gene products would allow for the genetic engineering of plants with a variety of desirable traits. The present invention addresses these and other needs.

#### SUMMARY OF THE INVENTION

This invention relates to polynucleotides encoding PNI (proline-rich NPR1 interactor) polypeptides as well as polypeptides that interact with the polypeptides PNI or MN1, a rice bZIP protein that interacts with *Arabidopsis* NPR1. The invention also relates to transgenic plants containing such polynucleotides. The invention also relates to methods of enhancing resistance to pathogens in a plant by introducing the above-described polynucleotides into a plant and selecting for plants with enhanced resistance.

The present invention provides an isolated nucleic acid construct comprising a polynucleotide sequence that is at least 50% identical to a polynucleotide selected from the group comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, and SEQ ID NO:17; or encodes a polypeptide selected from the group comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, and SEQ ID NO:18. In one embodiment of the invention the

polynucleotide is from a rice plant. In another embodiment, the construct further comprises a promoter operably linked to the polynucleotide sequence.

The invention also provides transgenic plants comprising a recombinant expression cassette comprising a plant promoter operably linked to a polynucleotide sequence that encodes a polypeptide wherein the polynucleotide: is at least 50% identical to a polynucleotide selected from the group comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, and SEQ ID NO:17; or encodes a polypeptide selected from the group comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, and SEQ ID NO:18. In one embodiment, the transgenic plant is rice.

The invention also provides a method of enhancing resistance to pathogens in a plant comprising two steps. One step involves introducing into the plant a recombinant expression cassette comprising a plant promoter operably linked to a polynucleotide sequence, wherein the polynucleotide sequence is at least 50% identical to a polynucleotide selected from the group comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, and SEQ ID NO:17; or encodes a polypeptide selected from the group comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, and SEQ ID NO:18. The second step involves selecting a plant with enhanced resistance.

### Definitions

“Enhanced disease resistance” refers to an increase in the ability of a plant to prevent pathogen infection or pathogen-induced symptoms. Enhanced resistance can be increased resistance relative to a particular pathogen species or genus or can be increased resistance to all pathogens (e.g., systemic acquired resistance).

One of skill in the art will recognize that a polypeptide is “capable of interacting” with another polypeptide in a number of different ways. This interaction can, for instance, be a direct protein-protein interaction. Typical bonds formed in a protein-protein interaction include hydrogen, ionic, van der Waals and covalent bonds. Alternatively, the interaction may be indirect. For instance, a third polypeptide may bind to both polypeptides, thereby keeping all three polypeptides in proximity to one another. Protein interactions can be measured by a number of different methods that are known to

those of ordinary skill in the art. Examples of systems to measure such interactions include, *inter alia*, the yeast two-hybrid system (see, *e.g.*, Fields, *Nature* 340(6230):245-6 (1989) and Finley, R. L. JR & Brent R. (1996) in *DNA Cloning – Expression Systems: A Practical Approach*, eds. Glover D. & Hames B. D (Oxford University Press, Oxford, England), pp. 169-203), immunoprecipitation (see, *e.g.*, Current Protocols in Molecular Biology Volumes 2, § 10.16, John Wiley & Sons, Inc. (1994-1998)), or the use of various sequence tags (*e.g.*, TAG, His, etc.) that allow for the isolation of interacting polypeptides under nondenaturing conditions (see, *e.g.*, Chen & Hai *Gene* 139(1):73-5 (1994); and Current Protocols in Molecular Biology Volumes 2, §§ 10.11A-B, 10.15, John Wiley & Sons, Inc. (1994-1998)). These methods can therefore be used to identify proteins that interact with polypeptides of the invention. One of ordinary skill in the art will recognize that protein-protein interactions can be measured by any number of methods and are not limited to those described above.

The phrase "nucleic acid sequence" refers to a single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. It includes chromosomal DNA, self-replicating plasmids, infectious polymers of DNA or RNA and DNA or RNA that performs a primarily structural role.

The term "promoter" refers to regions or sequence located upstream and/or downstream from the start of transcription and which are involved in recognition and binding of RNA polymerase and other proteins to initiate transcription. A "plant promoter" is a promoter capable of initiating transcription in plant cells.

The term "plant" includes whole plants, shoot vegetative organs/structures (*e.g.* leaves, stems and tubers), roots, flowers and floral organs/structures (*e.g.* bracts, sepals, petals, stamens, carpels, anthers and ovules), seed (including embryo, endosperm, and seed coat) and fruit (the mature ovary), plant tissue (*e.g.* vascular tissue, ground tissue, and the like) and cells (*e.g.* guard cells, egg cells, trichomes and the like), and progeny of same. The class of plants that can be used in the method of the invention is generally as broad as the class of higher and lower plants amenable to transformation techniques, including angiosperms (monocotyledonous and dicotyledonous plants), gymnosperms, ferns, and multicellular algae. It includes plants of a variety of ploidy levels, including aneuploid, polyploid, diploid, haploid and hemizygous.

A polynucleotide sequence is "heterologous to" an organism or a second polynucleotide sequence if it originates from a foreign species, or, if from the same species, is modified from its original form. For example, a promoter operably linked to a

heterologous coding sequence refers to a coding sequence from a species different from that from which the promoter was derived, or, if from the same species, a coding sequence which is not naturally associated with the promoter (*e.g.* a genetically engineered coding sequence or an allele from a different ecotype or variety).

“Recombinant” refers to a human manipulated polynucleotide or a copy or complement of a human manipulated polynucleotide. For instance, a recombinant expression cassette comprising a promoter operably linked to a second polynucleotide may include a promoter that is heterologous to the second polynucleotide as the result of human manipulation (*e.g.*, by methods described in Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, (1989) or Current Protocols in Molecular Biology Volumes 1-3, John Wiley & Sons, Inc. (1994-1998)) of an isolated nucleic acid comprising the expression cassette. In another example, a recombinant expression cassette may comprise polynucleotides combined in such a way that the polynucleotides are extremely unlikely to be found in nature. For instance, human manipulated restriction sites or plasmid vector sequences may flank or separate the promoter from the second polynucleotide. One of skill will recognize that polynucleotides can be manipulated in many ways and are not limited to the examples above.

A polynucleotide “exogenous to” an individual plant is a polynucleotide which is introduced into the plant by any means other than by a sexual cross. Examples of means by which this can be accomplished are described below, and include *Agrobacterium*-mediated transformation, biolistic methods, electroporation, and the like. Such a plant containing the exogenous nucleic acid is referred to here as a T<sub>1</sub> (*e.g.* in *Arabidopsis* by vacuum infiltration) or R<sub>0</sub> (for plants regenerated from transformed cells *in vitro*) generation transgenic plant. Transgenic plants that arise from sexual cross or by selfing are descendants of such a plant.

A “PNI” polypeptide of the invention is a subsequence or full length polypeptide sequence (SEQ ID NO:2) encoded by a polynucleotide (*e.g.*, SEQ ID NO:1).

An “NH1” polypeptide of the invention is a subsequence or full length polypeptide sequence (SEQ ID NO:4) encoded by a polynucleotide (*e.g.*, SEQ ID NO:3).

An “NH2” polypeptide of the invention is a subsequence or full length polypeptide sequence (SEQ ID NO:6) encoded by a polynucleotide (*e.g.*, SEQ ID NO:5).



An "MN1" polypeptide of the invention is a subsequence or full length polypeptide sequence (SEQ ID NO:20) encoded by a polynucleotide (e.g., SEQ ID NO:19).

In the case of both expression of transgenes and inhibition of endogenous genes (e.g., by antisense, or co-suppression) one of skill will recognize that the inserted polynucleotide sequence need not be identical, but may be only "substantially identical" to a sequence of the gene from which it was derived. As explained below, these substantially identical variants are specifically covered when references are made to a nucleic acid of the invention.

In the case where the inserted polynucleotide sequence is transcribed and translated to produce a functional polypeptide, one of skill will recognize that because of codon degeneracy a number of polynucleotide sequences will encode the same polypeptide. Thus, for instance, variants of NH1 are specifically covered by the terms "NH1 nucleic acid", "NH1 polynucleotide" and their equivalents. In addition, such terms specifically include those full length sequences substantially identical (determined as described below) with, for instance, a NH1 polynucleotide sequence and that encode proteins that retain the function of the NH1 polypeptide (e.g., resulting from conservative substitutions of amino acids in the NH1 polypeptide).

A "defense-related" gene refers to a plant nucleic acid whose expression increases when a plant is contacted with, or infected by, a pathogen. One of ordinary skill in the art will recognize that defense-related genes encode polypeptides with diverse predicted functions. Typically, defense-related genes encode polypeptides that may inhibit or destroy an invading pathogen or pathogen product. For instance, several defense-related genes are predicted to encode chitinases that can destroy the cell wall of invading fungal pathogens. The expression of many defense related genes is also induced or increased upon exposure to salicylic acid (SA) or SA analogs such as 2,6-dichloroisonicotinic acid (INA). Examples of defense-related genes include genes that encode pathogenesis-related proteins (PR) (see, e.g., Ward, *et al. Plant Cell* 3:1085-1094 (1991); Reuber *et al. Plant J.* 16(4):473-85 (1998); Heitz T, *et al. Mol Gen Genet* 245(2):246-54 (1994); and Stintzi *et al. Biochimie* 75(8):687-706 (1993)). Pathogenesis proteins include several proteins with homology to proteins with functions including  $\beta$ -1, 3-glucanase and chitinases. Not all PR proteins have predicted functions (e.g., PR-1). Other examples of defense related genes include those encoding phytoalexins,

phenylalanine ammonia lyase (PAL), proteinases, peroxidases, glutathione-S transferases, lipoxygenases, as well as genes such as the rice Pir7b gene (see, e.g., Waspi, *et al.*, *Eur. J. Biochem.* 254(1):32-7 (1998)), and SRG1 and SRG2 from alfalfa (see, e.g., Truesdell & Dickman, *Plant Mol Biol.* 33(4):737-43 (1997)), which were identified by the

characteristic of induction upon pathogen infection. See, e.g., Hunt, *et al.* *Gene* 179(1):89-95 (1996); Fluhr, *et al.* *Biochem Soc Symp* 60:131-41 (1994); Bowles, *et al.* *Annu Rev Biochem* 59:873-907 (1990); Glazebrook, *et al.* *Annu Rev Genet* 31:547-69 (1997); Dixon, R., *et al.*, *Adv Genet.* 28:165-234 (1990); Ward, E., *et al.*, *Plant Cell* 3:1085-1094 (1991); Lawton, *et al.*, *Plant J.* 10:71-82 (1996); and Friedrich, L., *et al.*, *Plant J.* 10:61-70 (1996) for additional examples and reviews of defense-related genes.

"Pathogens" include, but are not limited to, viruses, bacteria, nematodes, fungi or insects (see, e.g., Agrios, *Plant Pathology* (Academic Press, San Diego, CA) 1988).

Two nucleic acid sequences or polypeptides are said to be "identical" if the sequence of nucleotides or amino acid residues, respectively, in the two sequences is the same when aligned for maximum correspondence as described below. The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence over a comparison window, as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. When percentage of sequence identity is used in reference to proteins or peptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions, where amino acids residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated according to, e.g., the algorithm of

Meyers & Miller, *Computer Applic. Biol. Sci.* 4:11-17 (1988) e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, California, USA).

The phrase "substantially identical," in the context of two nucleic acids or polypeptides, refers to sequences or subsequences that have at least 60%, preferably 80%, most preferably 90-95% nucleotide or amino acid residue identity when aligned for maximum correspondence over a comparison window as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. This definition also refers to the complement of a test sequence, which has substantial sequence or subsequence complementarity when the test sequence has substantial identity to a reference sequence.

One of skill in the art will recognize that two polypeptides can also be "substantially identical" if the two polypeptides are immunologically similar. Thus, overall protein structure may be similar while the primary structure of the two polypeptides display significant variation. Therefore a method to measure whether two polypeptides are substantially identical involves measuring the binding of monoclonal or polyclonal antibodies to each polypeptide. Two polypeptides are substantially identical if the antibodies specific for a first polypeptide bind to a second polypeptide with an affinity of at least one third of the affinity for the first polypeptide.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment

algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection.

One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, *J. Mol. Evol.* 35:351-360 (1987). The method used is similar to the method described by Higgins & Sharp, *CABIOS* 5:151-153 (1989). The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. For example, a reference sequence can be compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps.

Another example of algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment

score can be increased. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The

5 BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (*see* Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

10 The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (*see, e.g.,* Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.  
15 For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

"Conservatively modified variants" applies to both amino acid and nucleic  
20 acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein.  
25 For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a  
30 polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.

As to amino acid sequences, one of skill will recognize that individual substitutions, in a nucleic acid, peptide, polypeptide, or protein sequence which alters a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art.

The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

(see, e.g., Creighton, *Proteins* (1984)).

An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below.

The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).

The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acid, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, *Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes*, "Overview of principles of hybridization and the strategy of nucleic acid assays"

(1993). Generally, highly stringent conditions are selected to be about 5-10°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength pH.

Low stringency conditions are generally selected to be about 15-30 °C below the  $T_m$ . The

$T_m$  is the temperature (under defined ionic strength, pH, and nucleic concentration) at

5 which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at  $T_m$ , 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt

concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about

10 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the

addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, preferably 10 time

background hybridization.

15 Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions.

20 In the present invention, genomic DNA or cDNA comprising *ANT* nucleic acids of the invention can be identified in standard Southern blots under stringent conditions using the nucleic acid sequences disclosed here. For the purposes of this disclosure, suitable stringent conditions for such hybridizations are those which include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and at least one

25 wash in 0.2X SSC at a temperature of at least about 50°C, usually about 55°C to about 60°C, for 20 minutes, or equivalent conditions. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency.

30 Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides that they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary “moderately stringent hybridization conditions” include a hybridization in a buffer of

40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency.

5 A further indication that two polynucleotides are substantially identical is if the reference sequence, amplified by a pair of oligonucleotide primers, can then be used as a probe under stringent hybridization conditions to isolate the test sequence from a cDNA or genomic library, or to identify the test sequence in, *e.g.*, an RNA gel or DNA gel blot hybridization analysis.

## 10 DESCRIPTION OF THE SPECIFIC EMBODIMENTS

The present invention provides the first identification and characterization of the rice polypeptide sequence, PNI. The present invention also provides the first identification and characterization of the rice polypeptide sequences that interact with the polypeptides PNI and MN1. The present invention also provides the polynucleotide sequences encoding such polypeptides as well as methods of enhancing resistance to pathogens by introducing the polynucleotides into plants. PNI and MN1 were originally identified by their characteristics of interacting with the *Arabidopsis* NPR1 polypeptide in a yeast two hybrid system.

20 The present invention provides for polynucleotides that encode three polypeptides that interact with MN1. One polypeptide, MAP1A, has homology to rat microtubule associated protein 1A. The two other polypeptides, GRL1 and GRL2, have homology to glutaredoxin proteins.

25 The present invention also provides for polynucleotides that encode five polypeptides that interact with PNI. Two of the polypeptides, NH1 and NH2 have homology to the *Arabidopsis* NPR1 protein. Of the remaining three polypeptides, one has homology to *Arabidopsis* nucleolins, one has homology to the *Arabidopsis* PREG-like protein, and the third does not display homology with any known polypeptide sequence.

### 30 Increasing polypeptide activity or gene expression

Any of a number of means well known in the art can be used to increase activity of polypeptides or polynucleotides of the invention in plants. Enhanced expression is useful, for example, to enhance systemic resistance to pathogens. Any



organ can be targeted, such as shoot vegetative organs/structures (*e.g.* leaves, stems and tubers), roots, flowers and floral organs/structures (*e.g.* bracts, sepals, petals, stamens, carpels, anthers and ovules), seed (including embryo, endosperm, and seed coat) and fruit. Alternatively, one or several genes of the invention can be expressed constitutively (*e.g.*,  
5 using the CaMV 35S promoter).

Increased activity or expression of polypeptides of polynucleotides of the invention can also be used to enhance resistance of plants to specific pathogens. For instance, expression of gene products that interact with PNI or MN1 can be targeted to induce defense-related genes harmful to specific pathogens.

#### 10 Increasing gene expression

Isolated sequences prepared as described herein can be used to introduce expression of a particular nucleic acid to increase gene expression using methods well known to those of skill in the art. Preparation of suitable constructs and means for introducing them into plants are described below.

15 One of skill will recognize that the polypeptides encoded by the genes of the invention, like other proteins, have different domains that perform different functions. Thus, gene sequences of the invention need not be full length, so long as the desired functional domain of the protein is expressed.

Modified protein chains can also be readily designed utilizing various  
20 recombinant DNA techniques well known to those skilled in the art and described in detail below. For example, the chains can vary from the naturally occurring sequence at the primary structure level by amino acid substitutions, additions, deletions, and the like. These modifications can be used in a number of combinations to produce the final modified protein chain.

#### 25 Modification of endogenous genes of the invention

Methods for introducing genetic mutations into plant genes and selecting plants with desired traits are well known. For instance, seeds or other plant material can be treated with a mutagenic chemical substance, according to standard techniques. Such chemical substances include, but are not limited to, the following: diethyl sulfate,  
30 ethylene imine, ethyl methanesulfonate and N-nitroso-N-ethylurea. Alternatively, ionizing radiation from sources such as, X-rays, fast neutrons or gamma rays can be used.

Alternatively, homologous recombination can be used to induce targeted gene modifications by specifically targeting gene of the invention *in vivo* (*see, generally*, Grewal and Klar, *Genetics* 146: 1221-1238 (1997) and Xu *et al.*, *Genes Dev.* 10: 2411-

2422 (1996)). Homologous recombination has been demonstrated in plants (Puchta *et al.*, *Experientia* 50: 277-284 (1994), Swoboda *et al.*, *EMBO J.* 13: 484-489 (1994); Offringa *et al.*, *Proc. Natl. Acad. Sci. USA* 90: 7346-7350 (1993); and Kempin *et al.* *Nature* 389:802-803 (1997)).

5 In applying homologous recombination technology to the genes of the invention, mutations in selected portions of a gene sequence of the invention (including 5' upstream, 3' downstream, and intragenic regions) such as those disclosed here are made *in vitro* and then introduced into the desired plant using standard techniques. Since the efficiency of homologous recombination is known to be dependent on the vectors used, 10 use of dicistronic gene targeting vectors as described by Mountford *et al.*, *Proc. Natl. Acad. Sci. USA* 91: 4303-4307 (1994); and Vaulont *et al.*, *Transgenic Res.* 4: 247-255 (1995) are conveniently used to increase the efficiency of selecting for altered gene expression in transgenic plants. The mutated gene will interact with the target wild-type gene in such a way that homologous recombination and targeted replacement of the wild- 15 type gene will occur in transgenic plant cells, resulting in suppression of activity associated with a wild type gene of the invention.

Alternatively, oligonucleotides composed of a contiguous stretch of RNA and DNA residues in a duplex conformation with double hairpin caps on the ends can be used. The RNA/DNA sequence is designed to align with the sequence of the target gene 20 and to contain the desired nucleotide change. Introduction of the chimeric oligonucleotide on an extrachromosomal T-DNA plasmid results in efficient and specific gene conversion directed by chimeric molecules in a small number of transformed plant cells. This method is described in Cole-Strauss *et al.*, *Science* 273:1386-1389 (1996) and Yoon *et al.* *Proc. Natl. Acad. Sci. USA* 93: 2071-2076 (1996).

25 Other means for increasing activity of polynucleotides and polypeptides of the invention

One method to increase expression of genes of the invention is to use "activation mutagenesis" (*see, e.g.* Hiyashi *et al.* *Science* 258:1350-1353 (1992)). In this method an endogenous gene of the invention can be modified to be expressed 30 constitutively, ectopically, or excessively by insertion of T-DNA sequences that contain strong/constitutive promoters upstream of the endogenous gene. As explained below, preparation of transgenic plants overexpressing a gene of the invention can also be used to increase expression of that gene. Activation mutagenesis of the endogenous gene of the invention will give the same effect as overexpression of a transgenic nucleic acid of

the invention in transgenic plants. Alternatively, an endogenous gene encoding an enhancer of activity or expression of an endogenous gene of the invention can be modified to be expressed by insertion of T-DNA sequences in a similar manner and activity of genes or polypeptides of the invention can be increased.

Another strategy to increase gene expression can be the use of dominant hyperactive mutants of a gene of the invention by expressing modified transgenes. For example, expression of modified NH1 with a defective domain that is important for interaction with a negative regulator of NH1 activity can be used to generate dominant hyperactive NH1 proteins. Alternatively, expression of truncated NH1 proteins which have only a domain that interacts with a negative regulator can titrate the negative regulator and thereby increase endogenous NH1 activity. Use of dominant mutants to hyperactivate target genes is described in Mizukami *et al. Plant Cell* 8:831-845 (1996).

#### Inhibition of activity or expression of polynucleotides or polypeptides of the invention

Activity of polynucleotides or polypeptides of the invention is important in modulating, directly or indirectly, the expression of a number of defense-related genes through interaction with the genes' promoters as well as with other proteins (*e.g.*, RNA polymerase, transcription factors and the like). For those polynucleotides or polypeptides of the invention that act to down regulate defense-related genes, inhibition of such gene expression activity can be used, for instance, to increase pathogen resistance in plants. Alternatively, inhibition of polynucleotides or polypeptides of the invention that activate defense related genes can reduce pathogen resistance in plants. In particular, targeted expression of nucleic acids of the invention that inhibit endogenous gene expression (*e.g.*, antisense or co-suppression) can be used to reduce pathogen resistance.

#### Inhibition of gene expression

The nucleic acid sequences disclosed here can be used to design nucleic acids useful in a number of methods to inhibit expression of genes of the invention in plants. For instance, antisense technology can be conveniently used. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the antisense strand of RNA will be transcribed. The construct is then transformed into plants and the antisense strand of RNA is produced. In plant cells, it has been suggested that antisense suppression can act at all levels of gene regulation including suppression of RNA translation (*see*, Bourque, *Plant Sci. (Limerick)* 105: 125-149 (1995); Pantopoulos, *In Progress in Nucleic Acid Research and Molecular Biology*,

Vol. 48. Cohn, W. E. and K. Moldave (Ed.). Academic Press, Inc.: San Diego, California, USA; London, England, UK. p. 181-238; Heiser *et al.*, *Plant Sci. (Shannon)* 127: 61-69 (1997)) and by preventing the accumulation of mRNA which encodes the protein of interest, (*see*, Baulcombe, *Plant Mol. Bio.* 32:79-88 (1996); Prins and Goldbach, *Arch. Virol.* 141: 2259-2276 (1996); Metzlaff *et al.* *Cell* 88: 845-854 (1997), Sheehy *et al.*, *Proc. Nat. Acad. Sci. USA*, 85:8805-8809 (1988), and Hiatt *et al.*, U.S. Patent No. 4,801,340).

The nucleic acid segment to be introduced generally will be substantially identical to at least a portion of the endogenous gene or genes (e.g., NH1, PNI, etc.) to be repressed. The sequence, however, need not be perfectly identical to inhibit expression. The vectors of the present invention can be designed such that the inhibitory effect applies to other genes within a family of genes exhibiting identity or substantial identity to the target gene.

For antisense suppression, the introduced sequence also need not be full length relative to either the primary transcription product or fully processed mRNA. Generally, higher identity can be used to compensate for the use of a shorter sequence. Furthermore, the introduced sequence need not have the same intron or exon pattern, and identity of non-coding segments may be equally effective. Normally, a sequence of between about 30 or 40 nucleotides to about the full length of a nucleotide should be used, though a sequence of at least about 100 nucleotides is preferred, a sequence of at least about 200 nucleotides is more preferred, and a sequence of about 500 to about 3500 nucleotides is especially preferred.

A number of gene regions can be targeted to suppress expression of genes of the invention. The targets can include, for instance, the coding regions, introns, sequences from exon/intron junctions, 5' or 3' untranslated regions, and the like.

Another well-known method of suppression is sense co-suppression. Introduction of nucleic acid configured in the sense orientation has been recently shown to be an effective means by which to block the transcription of target genes. For an example of the use of this method to modulate expression of endogenous genes (*see*, Assaad *et al.*, *Plant Mol. Bio.* 22: 1067-1085 (1993); Flavell, *Proc. Natl. Acad. Sci. USA* 91: 3490-3496 (1994); Stam *et al.*, *Annals Bot.* 79: 3-12 (1997); Napoli *et al.*, *The Plant Cell* 2:279-289 (1990); and U.S. Patents Nos. 5,034,323, 5,231,020, and 5,283,184).

The suppressive effect may occur where the introduced sequence contains no coding sequence *per se*, but only intron or untranslated sequences homologous to

sequences present in the primary transcript of the endogenous sequence. The introduced sequence generally will be substantially identical to the endogenous sequence intended to be repressed. This minimal identity will typically be greater than about 65%, but a higher identity might exert a more effective repression of expression of the endogenous

5 sequences. Substantially greater identity of more than about 80% is preferred, though about 95% to absolute identity is most preferred. As with antisense regulation, the effect should apply to any other proteins within a similar family of genes exhibiting identity or substantial identity.

10 For co-suppression, the introduced sequence, needing less than absolute identity, also need not be full length, relative to either the primary transcription product or fully processed mRNA. This may be preferred to avoid concurrent production of some plants that over-express the introduced sequence. A higher identity in a sequence shorter than full-length compensates for a longer, less identical sequence. Furthermore, the introduced sequence need not have the same intron or exon pattern, and identity of non-

15 coding segments will be equally effective. Normally, a sequence of the size ranges noted above for antisense regulation is used. In addition, the same gene regions noted for antisense regulation can be targeted using co-suppression technologies.

Oligonucleotide-based triple-helix formation can also be used to disrupt expression of genes of the invention. Triplex DNA can inhibit DNA transcription and replication, generate site-specific mutations, cleave DNA, and induce homologous recombination (*see, e.g.,* Havre and Glazer *J. Virology* 67:7324-7331 (1993); Scanlon *et al. FASEB J.* 9:1288-1296 (1995); Giovannangeli *et al. Biochemistry* 35:10539-10548 (1996); Chan and Glazer *J. Mol. Medicine (Berlin)* 75: 267-282 (1997)). Triple helix DNAs can be used to target the same sequences identified for antisense regulation.

25 Catalytic RNA molecules or ribozymes can also be used to inhibit expression of genes. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it

30 a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs. Thus, ribozymes can be used to target the same sequences identified for antisense regulation.

A number of classes of ribozymes have been identified. One class of ribozymes is derived from a number of small circular RNAs that are capable of self-

cleavage and replication in plants. The RNAs replicate either alone (viroid RNAs) or with a helper virus (satellite RNAs). Examples include RNAs from avocado sunblotch viroid and the satellite RNAs from tobacco ringspot virus, lucerne transient streak virus, velvet tobacco mottle virus, solanum nodiflorum mottle virus and subterranean clover mottle virus. The design and use of target RNA-specific ribozymes is described in Zhao and Pick, *Nature* 365:448-451 (1993); Eastham and Ahlering, *J. Urology* 156:1186-1188 (1996); Sokol and Murray, *Transgenic Res.* 5:363-371 (1996); Sun *et al.*, *Mol. Biotechnology* 7:241-251 (1997); and Haseloff *et al.*, *Nature*, 334:585-591 (1988).

#### Modification of endogenous genes of the invention

Methods for introducing genetic mutations described above can also be used to select for plants with decreased expression of genes of the invention.

#### Other means for inhibiting polynucleotide or polypeptide activity

Activity of polynucleotides of the invention may be modulated by eliminating the proteins that are required for cell-specific expression of such polynucleotides. Thus, expression of regulatory proteins and/or the sequences that control gene (e.g., NH1, NH2, PNI, etc.) expression can be modulated using the methods described here.

Another strategy is to inhibit the ability of a protein of the invention to interact with itself or with other proteins. This can be achieved, for instance, using antibodies specific to a polypeptide of the invention. In this method expression of antibodies specific for a polypeptide of the invention is used to inactivate functional domains through antibody:antigen recognition (*see*, Hupp *et al.*, *Cell* 83:237-245 (1995)). Interference with activity of protein(s) that interact with polypeptides of the invention can be applied in a similar fashion. Alternatively, dominant negative alleles (i.e. dominant gain of function mutants) of the genes of the invention can be prepared by expressing a transgene that encodes a truncated polypeptide. For example, a dominant negative allele of NH1 can be created by expressing a truncated NH1 polypeptide. Use of dominant negative mutants to inactivate target genes in transgenic plants is described in Mizukami *et al.*, *Plant Cell* 8:831-845 (1996).

#### Purification of polypeptides

Naturally occurring or recombinant polypeptides of the invention can be purified for use in functional assays. Naturally occurring polypeptides can be purified, e.g., from plant tissue and any other source of the desired polypeptide. Recombinant polypeptides can be purified from any suitable expression system.

The polypeptides of the invention may be purified to substantial purity by standard techniques, including selective precipitation with such substances as ammonium sulfate; column chromatography, immunopurification methods, and others (see, e.g., Scopes, *Protein Purification: Principles and Practice* (1982); U.S. Patent No. 4,673,641; Ausubel *et al.*, *supra*; and Sambrook *et al.*, *supra*).

A number of procedures can be employed when recombinant polypeptides are being purified. For example, proteins having established molecular adhesion properties can be reversibly fused to polypeptides of the invention. With the appropriate ligand, the such polypeptides can be selectively adsorbed to a purification column and then freed from the column in a relatively pure form. The fused protein is then removed by enzymatic activity. Finally the polypeptides of the invention could be purified using immunoaffinity columns.

#### Isolation of nucleic acids of the invention

Generally, the nomenclature and the laboratory procedures in recombinant DNA technology described below are those well known and commonly employed in the art. Standard techniques are used for cloning, DNA and RNA isolation, amplification and purification. Generally enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like are performed according to the manufacturer's specifications. These techniques and various other techniques are generally performed according to Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, (1989) or Current Protocols in Molecular Biology Volumes 1-3, John Wiley & Sons, Inc. (1994-1998).

The isolation of nucleic acids of the invention may be accomplished by a number of techniques. For instance, oligonucleotide probes based on the sequences disclosed here can be used to identify the desired gene in a cDNA or genomic DNA library. To construct genomic libraries, large segments of genomic DNA are generated by random fragmentation, e.g. using restriction endonucleases, and are ligated with vector DNA to form concatemers that can be packaged into the appropriate vector. To prepare a cDNA library, mRNA is isolated from the desired organ, such as leaves, and a cDNA library that contains a gene transcript of the invention is prepared from the mRNA. Alternatively, cDNA may be prepared from mRNA extracted from other tissues in which genes of the invention or homologs are expressed.

The cDNA or genomic library can then be screened using a probe based upon the sequence of a cloned gene of the invention as disclosed here. Probes may be

used to hybridize with genomic DNA or cDNA sequences to isolate homologous genes in the same or different plant species. Alternatively, antibodies raised against a polypeptide of the invention can be used to screen an mRNA expression library.

Alternatively, the nucleic acids of interest can be amplified from nucleic acid samples using amplification techniques. For instance, polymerase chain reaction (PCR) technology can be used to amplify the sequences of genes of the invention directly from genomic DNA, from cDNA, from genomic libraries or cDNA libraries. PCR and other *in vitro* amplification methods may also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes. For a general overview of PCR, see *PCR Protocols: A Guide to Methods and Applications*. (Innis, M, Gelfand, D., Sninsky, J. and White, T., eds.), *Academic Press*, San Diego (1990). Appropriate primers and probes for identifying sequences of the invention from plant tissues are generated from comparisons of the sequences provided here (e.g. SEQ ID NO: 1, SEQ ID NO:3, etc.).

Polynucleotides may also be synthesized by well-known techniques as described in the technical literature. See, e.g., Carruthers *et al.*, *Cold Spring Harbor Symp. Quant. Biol.* 47:411-418 (1982), and Adams *et al.*, *J. Am. Chem. Soc.* 105:661 (1983). Double stranded DNA fragments may then be obtained either by synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.

#### Preparation of recombinant vectors

To use isolated sequences in the above techniques, recombinant DNA vectors suitable for transformation of plant cells are prepared. Techniques for transforming a wide variety of higher plant species are well known and described in the technical and scientific literature. See, for example, Weising *et al.* *Ann. Rev. Genet.* 22:421-477 (1988). A DNA sequence coding for the desired polypeptide, for example a cDNA sequence encoding a full length protein, will preferably be combined with transcriptional and translational initiation regulatory sequences which will direct the transcription of the sequence from the gene in the intended tissues of the transformed plant.

For example, for overexpression, a plant promoter fragment may be employed which will direct expression of the gene in all tissues of a regenerated plant.



Such promoters are referred to herein as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation.

Examples of constitutive promoters include the cauliflower mosaic virus (CaMV) 35S transcription initiation region, the 1'- or 2'- promoter derived from T-DNA of

5 *Agrobacterium tumefaciens*, and other transcription initiation regions from various plant genes known to those of skill. Constitutive promoters and regulatory elements can also be isolated from genes that are expressed constitutively or at least expressed in most if not all tissues of a plant. Such genes include, for example, *ACT11* from *Arabidopsis* (Huang *et al. Plant Mol. Biol.* 33:125-139 (1996)), *Cat3* from *Arabidopsis* (GenBank No. U43147, Zhong *et al., Mol. Gen. Genet.* 251:196-203 (1996)), the gene encoding stearoyl-acyl carrier protein desaturase from *Brassica napus* (Genbank No. X74782, Solocombe *et al. Plant Physiol.* 104:1167-1176 (1994)), *GPc1* from maize (GenBank No. X15596, Martinez *et al. J. Mol. Biol.* 208:551-565 (1989)), and *Gpc2* from maize (GenBank No. U45855, Manjunath *et al., Plant Mol. Biol.* 33:97-112 (1997)).

15 Alternatively, the plant promoter may direct expression of a nucleic acid of the invention in a specific tissue, organ or cell type (*i.e.* tissue-specific promoters) or may be otherwise under more precise environmental or developmental control (*i.e.* inducible promoters). Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions, elevated temperature, the presence of  
20 light, or sprayed with chemicals/hormones. Tissue-specific promoters can be inducible. Similarly, tissue-specific promoters may only promote transcription within a certain time frame of developmental stage within that tissue. Other tissue specific promoters may be active throughout the life cycle of a particular tissue. One of skill will recognize that a tissue-specific promoter may drive expression of operably linked sequences in tissues  
25 other than the target tissue. Thus, as used herein a tissue-specific promoter is one that drives expression preferentially in the target tissue or cell type, but may also lead to some expression in other tissues as well.

A number of tissue-specific promoters can also be used in the invention. For instance, promoters that direct expression of nucleic acids in leaves, roots or flowers  
30 are useful for enhancing resistance to pathogens that infect those organs. For expression of a polynucleotide of the invention in the aerial vegetative organs of a plant, photosynthetic organ-specific promoters, such as the *RBCS* promoter (Khouidi, *et al., Gene* 197:343, 1997), can be used. Root-specific expression of polynucleotides of the invention can be achieved under the control of the root-specific *ANR1* promoter (Zhang &

Forde, *Science*, 279:407, 1998). Any strong, constitutive promoters, such as the CaMV 35S promoter, can be used for the expression of polynucleotides of the invention throughout the plant.

If proper polypeptide expression is desired, a polyadenylation region at the 3'-end of the coding region should be included. The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA.

The vector comprising the sequences (*e.g.*, promoters or coding regions) from genes of the invention will typically comprise a marker gene that confers a selectable phenotype on plant cells. For example, the marker may encode biocide resistance, particularly antibiotic resistance, such as resistance to kanamycin, G418, bleomycin, hygromycin, or herbicide resistance, such as resistance to chlorosulfuron or Basta.

#### Production of transgenic plants

DNA constructs of the invention may be introduced into the genome of the desired plant host by a variety of conventional techniques. For example, the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation and microinjection of plant cell protoplasts, or the DNA constructs can be introduced directly to plant tissue using ballistic methods, such as DNA particle bombardment.

Microinjection techniques are known in the art and well described in the scientific and patent literature. The introduction of DNA constructs using polyethylene glycol precipitation is described in Paszkowski *et al. EMBO. J.* 3:2717-2722 (1984). Electroporation techniques are described in Fromm *et al. Proc. Natl. Acad. Sci. USA* 82:5824 (1985). Ballistic transformation techniques are described in Klein *et al. Nature* 327:70-73 (1987).

Alternatively, the DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional *Agrobacterium tumefaciens* host vector. The virulence functions of the *Agrobacterium tumefaciens* host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria. *Agrobacterium tumefaciens*-mediated transformation techniques, including disarming and use of binary vectors, are well described in the scientific literature. See, for example Horsch *et al. Science* 233:496-498 (1984), and Fraley *et al. Proc. Natl. Acad. Sci. USA* 80:4803 (1983) and *Gene Transfer to Plants*, Potrykus, ed. (Springer-Verlag, Berlin 1995).

Transformed plant cells which are derived by any of the above transformation techniques can be cultured to regenerate a whole plant which possesses the transformed genotype and thus the desired phenotype such as increased seed mass. Such regeneration techniques rely on manipulation of certain phytohormones in a tissue culture growth medium, typically relying on a biocide and/or herbicide marker that has been introduced together with the desired nucleotide sequences. Plant regeneration from cultured protoplasts is described in Evans et al., *Protoplasts Isolation and Culture, Handbook of Plant Cell Culture*, pp. 124-176, MacMillan Publishing Company, New York, 1983; and Binding, *Regeneration of Plants, Plant Protoplasts*, pp. 21-73, CRC Press, Boca Raton, 1985. Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee et al. *Ann. Rev. of Plant Phys.* 38:467-486 (1987).

The nucleic acids of the invention can be used to confer desired traits on essentially any plant. Thus, the invention has use over a broad range of plants, including species from the genera *Anacardium*, *Arachis*, *Asparagus*, *Atropa*, *Avena*, *Brassica*, *Citrus*, *Citrullus*, *Capsicum*, *Carthamus*, *Cocos*, *Coffea*, *Cucumis*, *Cucurbita*, *Daucus*, *Elaeis*, *Fragaria*, *Glycine*, *Gossypium*, *Helianthus*, *Heterocallis*, *Hordeum*, *Hyoscyamus*, *Lactuca*, *Linum*, *Lolium*, *Lupinus*, *Lycopersicon*, *Malus*, *Manihot*, *Majorana*, *Medicago*, *Nicotiana*, *Olea*, *Oryza*, *Panicum*, *Pennisetum*, *Persea*, *Phaseolus*, *Pistachia*, *Pisum*, *Pyrus*, *Prunus*, *Raphanus*, *Ricinus*, *Secale*, *Senecio*, *Sinapis*, *Solanum*, *Sorghum*, *Theobromus*, *Trigonella*, *Triticum*, *Vicia*, *Vitis*, *Vigna*, and *Zea*.

One of skill will recognize that after the expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.

Using known procedures one of skill can screen for plants of the invention by detecting the increase or decrease of mRNA or protein of the invention in transgenic plants. Means for detecting and quantitating mRNAs or proteins are well known in the art.

#### Methods of enhancing plant resistance to pathogens

The present invention provides for method of enhancing plant resistance to pathogens by modulating the expression and/or activity of polynucleotides and/or polypeptides of the invention. Without limiting the invention to a particular mechanism of operation, polypeptides of the invention are likely to act as direct or indirect

modulators of defense-related genes. Thus, resistance can be enhanced, for instance, by increased expression of positive regulators of defense-related genes. Alternatively, or in combination, polynucleotides or polypeptides of the invention can be modified to enhance resistance, *e.g.*, by increasing or decreasing the polypeptides' interactions with other components important in plant pathogen resistance.

Without limiting the invention to a particular mechanism of operation, one possible mechanism by which the polypeptides of the invention modulate resistance is, for example, by acting as components of a signal cascade between initiation of resistance and the development of the resistance response. For example, interaction of polypeptides of the invention with defense-related promoters may lead directly to increased transcription of defense-related transcripts, thereby enhancing resistance to pathogens.

Alternatively, polypeptides of the invention may interact with promoters of other genes as well as with other regulatory factors, thereby modulating expression of defense related genes or other genes involved in resistance. For example, after a plant component (*e.g.*, a plant disease resistance polypeptide) is activated by the presence of a pathogen (*e.g.* through an avirulence determinant, *see, e.g.*, Dangl, *Curr Top Microbiol Immunol* 192:99-118 (1994)), the plant component provides a signal (*e.g.*, via protein-protein interactions, phosphorylation/dephosphorylation, oxidative burst or the like) directly or indirectly, to the polypeptides of the invention (*e.g.* NH1, NH2, PNI, etc.). NH1, for example, may then activate MN1 and/or PNI polypeptides that in turn activate defense-related genes as well as polynucleotides and polypeptides of the invention (*e.g.*, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, and SEQ ID NO:18).

Alternatively, some polypeptides of the invention may act as negative regulator of a resistance response. Negative regulators act to prevent a resistance response by various mechanisms (*e.g.*, via protein-protein interactions, phosphorylation/dephosphorylation, etc.). For instance, polypeptides of the invention may act as transcriptional repressors, thereby allowing for the expression of defense-related genes. Such mechanisms may be altered when a plant is contacted with a pathogen, allowing a resistance response to develop.

#### Selecting for plants with enhanced resistance

Plants with enhanced resistance can be selected in many ways. One of ordinary skill in the art will recognize that the following methods are but a few of the possibilities. One method of selecting plants with enhanced resistance is to determine

resistance of a plant to a specific plant pathogen. Possible pathogens include, but are not limited to, viruses, bacteria, nematodes, fungi or insects (see, *e.g.*, Agrios, *Plant Pathology* (Academic Press, San Diego, CA) (1988)). One of skill in the art will recognize that resistance responses of plants vary depending on many factors, including what pathogen or plant is used. Generally, enhanced resistance is measured by the reduction or elimination of disease symptoms when compared to a control plant. In some cases, however, enhanced resistance can also be measured by the production of the hypersensitive response (HR) of the plant (see, *e.g.*, Staskawicz *et al. Science* 268(5211): 661-7 (1995)). Plants with enhanced resistance can produce an enhanced hypersensitive response relative to control plants.

Enhanced resistance can also be determined by measuring the increased expression of a gene operably linked a defense related promoter. Measurement of such expression can be measured by quantitating the accumulation of RNA or subsequent protein product (*e.g.*, using northern or western blot techniques, respectively (see, *e.g.*, Sambrook *et al.* and Ausubel *et al.*). A possible alternate strategy for measuring defense gene promoter expression involves operably linking a reporter gene to the promoter. Reporter gene constructs allow for ease of measurement of expression from the promoter of interest. Examples of reporter genes include:  $\beta$ -gal, GUS (see, *e.g.*, Jefferson, R. A., *et al.*, *EMBO J* 6: 3901-3907 (1987), green fluorescent protein, luciferase, and others.

The following Examples are offered by way of illustration, not limitation.

#### EXAMPLE 1

This example shows that four rice bZIP gene products, MN1, MN8, MN38 and MN140, and a proline-rich protein, PNI, bind to *Arabidopsis* NPR1 in the yeast two-hybrid system.

## RESULTS

### *Five rice polypeptides interact with NPR1 in the yeast two-hybrid system.*

A rice cDNA library prepared in the pAD-GAL4 vector was screened using a full-length Arabidopsis Npr1 cDNA as the bait. The *Arabidopsis* Npr1 bait was cloned into the SmaI and BglII sites of plasmid pMC86, which was constructed by replacing the GAL4 activation domain in pPC86 (Chevray, P.M. and Nathans, D., *Proc. Natl. Acad. Sci. USA* 89:5789-5793 (1992)) with the GAL4 DNA binding domain (GAL4DB) in pPC97 by using KpnI and SacI sites. NPR1 was expressed as a GAL4DB::NPR1 fusion protein in the yeast host HF7c (Clontech, Palo Alto, CA). The yeast two-hybrid screen was performed as described (Finley, R. L. *et al.* (1996) in *DNA Cloning – Expression Systems: A Practical Approach*, eds. Glover D. & Hames B. D (Oxford University Press, Oxford, England), pp. 169-203). After screening approximately 20 million yeast transformants, five independent clones were isolated that displayed histidine prototrophy and were lacZ positive. Each isolated clone was then used to transform HF7c together with the pMC86 plasmid or with pMC86 containing the bait, confirming specificity of the interaction. These clones are hereafter called PNI, MN1, MN8, MN38, and MN140.

The 5' ends of MN1 and MN8 cDNAs were obtained by running nested PCR reactions for each clones using the same rice library cDNA as the template. The primary reaction was carried out with anchor primer SS20 (5'AGGGATGTTTAATACTACTAC) and gene-specific primer mn1-1 (5'GAAGCCATGACTGCACCA) for MN1 or primer mn8-1 (5'TTATCGTCGGTATCCAGGA) for MN8. The secondary reaction used anchor primer ADR1 (5'ACCCGGGAGAGATCGAATTCGGCACGA) and gene-specific primer mn1-2 (5'CACCACTATGTCCGTTTTC) for MN1 or primer mn8-2 (5'GGACTGTTGATGTGTCAGT) for MN8. PCR products were cloned in the pCR-BluntII-TOPO (Invitrogen, Carlsbad, CA) plasmid vector. Two clones for each were sequenced. The MN8 clone obtained from two-hybrid screens appeared to contain the complete cDNA coding region when the sequences were compared. The MN1 sequence encoding the first 18 amino acids was combined with that of the original MN1 clone to give a complete cDNA coding sequence.

## EXAMPLE 2

This example shows the identification of three polypeptides that interact with MN1 in the yeast two-hybrid system.

### RESULTS

*Three polypeptides that interact with MN1 were identified.*

The rice cDNA library described above was rescreened using a truncated MN1, containing amino acids 98 to 334, as bait in the yeast two-hybrid system. The MN1 bait was cloned into the SmaI and SpeI sites of plasmid pMC86. MN1 was expressed as a GAL4DB::MN1 fusion protein in the yeast host HF7c. After screening approximately five million yeast transformants, twenty independent clones were isolated that displayed histidine prototrophy and were lacZ positive. After nucleotide sequence analysis, three unique predicted protein sequences were identified (see SEQ ID 14, SEQ ID NO:16 and SEQ ID NO:18, encoded by SEQ ID NO:13, SEQ ID NO:15 and SEQ ID NO:17, respectively). These clones are designated GRL1, GRL2 and MAP1A, respectively.

As suggested by their names, GRL1 and GRL2 demonstrate homology to glutaredoxin. MAP1A has partial homology with the rat microtubule associated protein 1A.

## EXAMPLE 3

This example shows the identification of five polypeptides that interact with PNI in the yeast two-hybrid system.

### RESULTS

*Five polypeptides that interact with PNI were identified.*

The rice cDNA library described above was again rescreened, this time using full length PNI as bait in the yeast two-hybrid system. The PNI bait was cloned into the SmaI and SpeI sites of plasmid pMC86. PNIs expressed as a GAL4DB::PNI fusion protein in the yeast host HF7c (Clontech, Palo Alto, CA). After screening approximately sixteen million yeast transformants, five independent clones were isolated that displayed histidine prototrophy and were lacZ positive.

After nucleotide sequence analysis, these five unique predicted protein sequences were identified (see SEQ ID 4, SEQ ID NO:6 and SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:12 encoded by SEQ ID NO:3, SEQ ID NO:5 and SEQ ID NO:7, SEQ ID NO:9, and SEQ ID NO:11, respectively). The first two clones have homology to

*Arabidopsis* NPR1 and therefore are called NH1 (NPR1 homolog 1), NH2 (NPR1 homolog 2). The third protein (SEQ ID NO:8) has homology to an *Arabidopsis* nucleolin-like protein. The fourth protein (SEQ ID NO:10) has homology to an *Arabidopsis* PREG-like protein. Finally, SEQ NO:12 does not have significant homology to anything in the current databases.

The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.

10



PNI

SEQ ID NO:1

Nucleotide sequence:

5 ATGGACGCCACCACCGACGCCACCACCGCCAAGCGCAAGCGCCAGCCG  
CCTCCGACATCGCCGACGACGCCCCACCACCGTCGACGAGGTCTCCGACGCCGAGGTCGAGG  
AGTTCTACGCCATCCTCCGCCGATGCGCGACGCCACCGACGGCTCGGCGCCCGCCCTCCCC  
CGCCGCGCGCGCCGGCGTGGCGCCCCAGCTTCTCCTGGGAGGACTTCGCCGACGCGCCGCCA  
AGCAGGCGCCGCCGCCGCGCAGAGCCCGCCGACCAGAGCGCGTCGCCGAGAACGCCACC  
10 CCGCCCCGCGCGCCCGGCGCCCGGCCCTCGACCTGAACGTCGAGCCGCCGTCCGACGCGCCGGCC  
ACGCCGCGCTCGGCGCGCGCCCGGCATAGGCGCGCGCCACGAGGAAACCGGGCGCGTCGCG  
CATGCGGGTGCTCACGGATTACAACTACTTTGCTAGCTAGAAGCAGCTAGCTGCAGTGTTGGA  
TTGATCCATCCATGGAGCTGCCTTGTCCTCTTGTTGTGAACAGGTGAGACCTGGTTAATCAA  
TCGCTCTTGCTGGGAAGAAACAATCCATTATTGGTCCCATCATGGAGATGTACTATCATGTACC  
15 AAGACAAAATGACGGGTTTAATTAATTACCCCTATATTATTCGTTCTGTAATTCAGTAAAAA  
AAAAAAAAAAAAAAAAAAAA

SEQ ID NO:2

Amino acid sequence:

20 MDATTTDATTAKRKRPAASDIADDAPTTVDEVSDAEVEEFYAILRRMRDATRRL  
GARPPPPRAPAWRPSFSWEDFADAPPKQAPPPQPADHERVAENATPPRRPAPGLDLNVEPPSDA  
PATPRSARAPA

Rice proteins that interact with the PNI protein:

NPR1 Homologue 1 (NH1)

SEQ ID NO:3

25 ATGGAGCCGCCGACCAGCCACGTCACCAACGCGTTCTCCGACTCGGACAGCG  
CGTCCGTGGAGGAGGGGGACGCCGACGCGGACGCCGACGTGGAGGCGCTCCGCCGCTCTCC  
30 GACAACTCGCCGCGGCGTTCCGCTCGCCCCGAGGACTTCGCGTTCCTCGCCGACGCGCGCATC  
GCCGTCCCGGGCGGCGGCGGCGGCGGCGGCGGCGACCTGCGGGTGACCGCTGCGTGCTCTCCGCG  
CGGAGCCCCCTTCTGCGCGGCGTCTTCGCGCGCCGCGCCGCCGCCGAGGCGGCGGCGGC  
GAGGATGGCAGCAGAGGCTGGAGCTCCGGGAGCTCCTCGGCGGCGGCGGCGAGGAGGTGGA  
GGTCGGGTACGAGGCGCTGCGGCTGGTGCTCGACTACCTCTACAGCGGCCGCGTCGGCGACCT  
35 GCCCAAGGCGGCGTGCTCTGCGTCGACGAGGACTGCGCCACGTCGGGTGCCACCCCGCCGT  
CGCGTTCATGGCGCAGGTCTCTTCGCCGCTCCACCTTCCAGGTCGCCGAGCTCACCAACCTC  
TTCCAGCGGCTCTCTTGATGTCTTGAAGTTGAAGTAGATAACCTTCTATTGATCTTAT  
CTGTTGCCAACTTATGCAACAAATCTTGATGAAACTGCTTGAAGATGCCTTGATATGGTAGT  
CCGGTCAAACCTTGACATGATTACTCTTGAGAAGTCATTGCCTCCAGATGTTATCAAGCAGATT  
40 ATTGATGCACGCCTAAGCCTCGGATTAATTTACCAGAAAAACAAGGGATTTCTTAACAAACAT  
GTGAGGAGGATACACAGAGCCCTTGACTCTGACGATGTAGAGCTAGTCAGGATGCTGCTCACT  
GAAGGACAGACAAATCTTGATGATGCGTTTGCACTGCACTACGCCGTCGAACATTGTGACTCC  
AAAATTACAACCGAGCTTTTGGATCTCGCACTTGCAAGATGTTAATCATAGAAACCCAAGAGGT  
TATACTGTTCTTACATTGCTGCGAGGCGAAGAGAGCCTAAAATCATTGTCTCCCTTTTAACCA  
45 AGGGGGCTCGACCAGCAGATGTTACATTCGATGGGAGAAAAGCGGTTCAAATCTCAAAAAGA  
CTAACAAAACAAGGGGATTACTTTGGGGTTACCGAAGAAGGAAAACCTTCTCCAAAAGATAG  
GTTATGTATTGAAATACTGGAGCAAGCTGAAAGAAGGGACCCACAACCTCGGAGAAGCATCAG  
TTTCTCTTGCAATGGCAGGTGAGAGTCTACAGGAAGGTTGCTGTATCTTGAAAACCGAGTTG  
CTTTGGCAAGGATTATGTTTCCGATGGAGGCAAGAGTAGCAATGGATATTGCTCAAGTGGATG  
50 GAACTTTGGAATTTAACCTGGGTCTGGTGCAATCCACCTCTGAAAGACAACGGACAACCTG  
TTGATCTAAATGAAAGTCCTTTTATAATGAAAGAAGAACACTTAGCTCGGATGACAGCACTCT  
CCAAAACAGTGGAGCTCGGGAACGCTTTTCCCGCGATGTTTGAACGTGCTCGACAAGATCA  
TGGATGATGAAACTGATCCGTTTCCCTCGGAAGAGACACGTCCGCGGAGAAGAGGAAGAGG  
TTTCATGACCTGCAGGATGTTCTTCAAGGACATTCACGAGGACAAGGAGGAGAATGACAG  
55 GTCGGGGCTCTCGTCGTCGTCATCGACATCGATCGGGGCCATTTCGACCAAGGAGATGAAC  
ACCATTGCTCCCAAATAGTTGCCAATATTGATAGCTAACTGTCTCTGAGCTACTACCTGAT  
GTTTGCTTCTGTCAATTGCCCCCAATATATTCTCAATGGTTTAGGCTTGTAAGTATTAGT  
TCTTACAGCTATTGCCCGTCAATTGTGAAACGCAGAAAGTTTCACTAGTGCTTGTAAGTATGAGT  
GTAATACAAGTGCTTGAATTTTGAAGTTGTAAGTTTCCAGTGTTTGTCTGTAAGTATGA  
60 GATGATTTCTTGCAAAAAAAAAAAAAAAAAAAAAA

Amino acid sequence:

SEQ ID NO:4

MEPPTSHVTNAFSDSDSASVEEGDADADADVEALRRLSDNLAAAFRSPEDFAFL  
ADARIAVPGGGGGGDLRVHRCVLSARSPFLRGVFAARRAAAAAGGGGEDGSRLELRELLGGGG  
EEVEVGYEALRLVLDYLYSGRVGDLPKAACLCVDEDCAHVGCHPAVAFMAQVLFMASTFQVAEL  
TNLFQRRLLDVLDKVEVDNLLLILSVANLNCNKSCMKLLERCLDMVVRNLDMITLEKSLPPDVIKQ  
IIDARLSLGLISPENKGFPNKHVRRIRALDSDDELVRMLLLEGQTNLDDAFALHYAVEHCDSKIT  
TELLDLALADVNRNPRGYTVLHIAARRREP KIIIVSLTKGARPADVTFDGRKAVQISKRLTKQGD  
YFGVTEEGKPSPKDRLCIEILEQAERRDPQLGEASVSLAMAGESLRGRLLYLENVRVALARIMFPME  
ARVAMDIAQVDGTLEFNLGSGANPPPERQRTTVDLNESPFIMKEEHLARMTALSKTVELGKRFFPR  
CSNVLDKIMDDETPVSLGRDTSAEKRKRFDLQDVLQKAFHEDKEENDRSGLSSSSSSSTSIGAIRP  
RR

NPR1 homologue 2 (NH2)

SEQ ID NO:5

Nucleotide sequence:

TACAATACAAAGATGGAGCAAGGCCAAGAGTCAAACAAAGACAGGTTATGT  
ATTGATATATTAGATAGGGAGATGATAAGGAAACCTATGGCAGTGGAAGATTCTGTCACCTCG  
CCTTTGTTGGCTGACGATCTTCACATGAAGCTTCTCTACCTTGAAAACAGAGTTGCATTTGCAA  
GATTATTTTTCTGTCAGAAAGCAAAGGTTGCAATGCAAATTGCACAAGCAGACACCACACCAG  
AATTTGGCATTGTTCTGTCAGCTAGCACTTCTGGAATAATTGAAGGAAGTCGATCTGAACGAGA  
CACCAGTAACACAAAACAAAAGGCTCCGTTCAAGGGTGGATGCACTCATGAAAACAGTTGAG  
CTGGGACGTCGCTACTTCCCTAACTGCTCGCAGGTGCTCGACAAATTTCTGGAGGATGATTTGC  
CCGATAGTCCTGATGCACTCGACCTCCAAAATGGCACTTCTGATGAGCAAAATGTTAAAAGGA  
TGCGGTTCTGTGAGTTAAAGGAGGATGTGCGCAAGGCATTGAGCAAAAGACAGAGCTGATAAT  
AGCATGTTTTCTATCTTGTATCTTCATCGTCCTCTTCGCCACCTCCCAAGGTTGCAAAGAAAT  
GACAGAAGTTTTGTAAACAAATTTCCGCTCGTGATGTTACTGGGACAAGAGATATCGATCAATA  
GACCTGTATAGTCTTACAGTGGTATAACAATTAGATATCGAAGCTTCTTCGAATATTAGAAAAG  
TGCTGTTCTGGGCTGCACTCAGCTGGTTTATGGGACCCATGCGGTGAAACTGGCAAAAGAAAA  
CCAGCTGATTAGAGGCTCCAAAGTAGTGTCTCTCGTGAATATGTTTGTAGCATTCTGTTTTGTT  
CAGGATGGCTGTAATGATAAAATCTTTTCAATAGATATATAGCTAATTGTCTCGTAAAAAAA  
AAAAAAAAAAAAAAAA

SEQ ID NO:6

Amino acid sequence:

YNTKMEQGQESNKDRLCIDILDREMIRKPMAVEDSVTSPLLADDLHMKLLYLEN  
RVAFARLFFPAEAKVAMQIAQADTTPEFGIVPAASTSGKLKEVDLNETPVTQNKRLRSRVDALMK  
TVELGRRYFPNCSQVLDKFLEDDLPDSDALDLQNGTSDEQNVKRMRFCELKEDVRKAFFSKDRAD  
NSMFSILSSSSSSPPPKVAKK

3. Nucleolin-like protein

SEQ ID NO:7

Nucleotide sequence:

GATGATAGAGTACCACTACCTAGTTCAAATGGAGCTCCATTGCTCCCGAGTTA  
TCCTCCACTTGGATATGGTATCATGTACGTACCAGGTGCCTATGGTGCTGCTCCTGCTAGTACT  
GCACAGCCTATGCTGTATGCTCCAAGAGCTCCTCCAGGGGAGCAATGGTTCCAATGATGTTA  
CCGGATGGTCATCTCGTATATGTTGTACAACAGCCTGGTGGACAGTTGCCGCTGGCTTCGCCGC  
CGCCGCAGCAAGCTGGACATCGTAGCGGCAGTGGAGGACGTCATGGCGGCAGTGGCAGCCGC  
TATGGCGGTGGTGGTGGCAGCTCCGGCAGTAGCAGGCCCGGTGCAAAACGGCAGAGAGGAGA  
TGACAACAGCAGTAGCCGCCACAAAGGCCGGCGCCGCGTACTGATCTGATCAGCATAGCTGT  
AGCTACCACTTAGAAGATGTAGTCCGCTCGCAGAAAATTACCAGAAAATCTGGTAGAAATAAT  
TTATACTGTTTGTACTCATCGATTTATTAGAAGAATTCGTTTCTGAAACAAGACTGTACATGCG  
TATTTACCAGTATTTTCCAATATCGCAGAATTGCTGAAAAAAA

SEQ ID NO:8

Amino acid sequence:

DDRVLPLSSNGAPLLPSYPPLGYGIMSVPGAYGAAPASTAQPMLYAPRAPPGAA  
MVPMMPLPDGHLVYVVQQPGGQLPLASPPQQAHRSGSGGRHGGSGSRYGGGGGSSGSSRPGAK  
RQRGDDNSSSRHKGRRRTDLISIAVATT

PREG-like protein

SEQ ID NO:9

Nucleotide sequence:

5 ATGGACGCCGCGCGGAGCTGGACATGGTGGCGCGCGCGTGCAGCGGCTGGTGGC  
GCGTCCGCTCCGCCCGCGCGGAGCTGGACATGGTGGCGCGCGCGTGCAGCGGCTGGTGGC  
GCGGAACGACGCGGTGGAGGCGCTGAGCGGCGGAGGGGAGGCGGCGGCGGGGCTAGGAGCA  
GGGATGGCGGCGTTCGAGGCGGCGAGGGGCGCGCGCGCGCGCATCGGCGTGGCGCAGTA  
10 TCTGGAGCGCGTGCACCGGTACGCCGGGCTGGAGCCGGAGTGCTACGTGGTGGCGTACGCGTA  
CGTCGACATGGCGGCGCACCGCCGCCCGCGCGCGCGTGCCTCCCGCAACGTCCACCGCCT  
CCTCCTCGCCTGCCTCCTCGTCGCCTCCAAGGTTCTCGACGACTTCCACCACAACAACGCGTTC  
TTCGCGCGCGTTCGGCGGCGTGAGCAACGCGGAGATGAACAGGCTGGAGCTGGAGCTCCTCGC  
CGTGCTGGACTTCGAGGTATGCTCAGCCACCGCGTCTACGAGCTCTACCACGAGCACCTCAA  
15 GAAGGAGGCGCGGAGGGACGGCGGCGCGCGGCGACATGCTCGCCGGCGCGTCCGCCCGCGCG  
CCGCCAAGGCGGGGAGAATGGCGGCGCGTCTCGCCGTCCAAGCTGCTGGAACGCGCGGCGGTG  
AACGGCGCGCGCAGCACGACGATGGAGGAGCCTGGGTACGGCGGCGGCGGCGGAGGCGG  
CGAACGCGCTGCGGCGGCACAGGTCGTCGTCGTCGTCGCGGTATTCCTTCGATTGCTAGTATA  
GCCAGCGTTGCCAAAGAGCGCGTTCGTGTGTATATATCAGGTTATCAACGAGAGTTTTTGAG  
20 GCTGTAAAAAAATTAAAGACGGATTAATTACCTGCCAAAGTGCCAATTAGCAAATGTTTCCCA  
TAAAAAAAAAAAAAAAAAAAAAAAAA

SEQ ID NO:10

Amino acid sequence:

25 MDAAAAAGGEMSRQKATASAPPPPELDMVARAVQRLVARNDAVEALSGGGEA  
AAGLGAGMAAFEAAARGAPAPRIGVAQYLERVHRYAGLEPECYVVAYAYVDMAAHRRPAAAVAS  
RNVHRLLLACLLVASKVLDDFHNNNAFFARVGGVSNAMNRLELELLAVLDFEVMLSHRVYELY  
HEHLKKEARRDGGAGDMLAGASAAAAAKAGRMAAVSPSKLLERAAVNGAAQHDDWRS LGTAA  
AAEAANGVRRHRSSSSSRYSFDC

Novel protein

SEQ ID NO:11

Nucleotide sequence:

30 AGTGCTAGTGATGAAGCCCTTGCAAAAGCAGCATCTCTGTATGGAGGTGCTCT  
AAGAAATGTTGAGAAAGAGTACGAAGAATTTAATAGAATTTTATCTTCTCAGACTATAGATCC  
35 ATTGAGGGCTATGGCTGCAGGCGCTCCCCTGGAAGATGCTCGTGGTCTTGACAAACGTTATAG  
CCGGATGAGACATGAAGCTGAGATCCTTTCTGCTGAAATTGCTAGAAGGAAGCAACGGGTAC  
GAGAAGCTCCAGTTGCTGAGCACACTACGAAGCTTCAACAGTCTGAATCTAAAATGATAGAGC  
ACAAAGCAAGCATGGCTGTGTTAGGAAAGGAAGCTGCTGCTGCACTTGCCGCTGTTGAATCTC  
AGCAGCAAAGGATAACTCTTCAGCGCCTGGTTGGCATGGTAGAAGCAGAAAAGTTATTTTCATT  
40 TGAGGTTAGCTGCTATACTTGATGATGTTGAAGCTGAGATGTCCTCTGAAAAGCAAAAGAGAG  
AATCTGCACCGCCTACTATTCTCATAAGCGTGCTGAGAAGGCCAGTACTTCTTGCTGA  
GGCGGTGCATAACTCAATGGTACCACAGAAAAGGAGTTGAGTTAATTGTGGTGATTATGTC  
G

SEQ ID NO:12

Amino acid sequence:

45 SASDEALAKAASLYGGALRNVEKEYEEFNRLSSQTIDPLRAMAAGAPLEDARGL  
AQRYSRMRHEAELS AEIARRKQRVREAPVAEHTTKLQQSESKMIEHKASMAVLGKEAAAALAAV  
50 ESQQQRITLQRLVGMVEAEKLFHLRLAAILDDVEAEMSSEKQKRESAPPTIHSKRAEKAQYFLAE  
AVHNFNGTTEKELSLIVVIMS

[illegible]

20 AVAESPVLVVGRRGCLIHVVKRLLQGLGVNPAVHEVAGEAALKGVVPAGGEAAALPAVFVGGK  
LLGGLDRLMAVHISGELVPILKKAGALWL

20 AVAESPVLVVGRRGCLIHVVKRLLQGLGVNPAVHEVAGEAALKGVVPAGGEAAALPAVFVGGK  
LLGGLDRLMAVHISGELVPILKKAGALWL

25 Nucleotide sequence:  
ATGTACCAGGCGATCCCGTACAACGCGAACCGGGCTTGGCCGGCGGCGAGCC  
GGCCGGCGACGGCGCCGCCGCCGCCGCCGCCGCTGGAGAGGAGGAGGAGGTGAGGAG  
GGCGGTGGCGAGTGCCCGGTGGTGGTGGTGGGTCGGAGCGGGTGCTGCCTGAGCCACGTCG  
TGAAGCGGCTGCTGCAGGGGCTCGGGGTCAACCCGGCGGTGCACGAGGTCGCCGGCGAGGCC  
30 GAGCTCGCCGGGTGGTCCGCGCGCGCGCGCGTCCGCTGCCGGCGGTGTTTCGTCGGCGG  
GAGGCTCCTCGCGGGGTCTGACCGGCTCATGGCCGTGCACATCTCCGGCGAGCTCGTGCCAT  
TCTGAAGGAGGCCGGTGCACTCTGGCTCTGA

35 Amino acid sequence:  
 MYQAIPYNANRAWPAASRPATAPPPPPPRGEEEEVRRVAECPVVVVGRSGCC  
 LSHVVKRLQLQGLGVNPAVHEVAGEAELAGVVAGGGGVALPAVFGGRLLGGLDRLMAVHISGEL  
 VPILKEAGALWL

55 SEQ ID NO:18  
Amino acid sequence:  
MGSSAADSFPAGGDDAIRDVYGIGGGGEEDDPSLFLYLSDLAPVSPSAYLDLPPSP  
PPPTTTATTMVKEGEEAPEDLVLPFISRMLEEDIDDKFFYDYPDNPALLQAQQPFLEILSDPSSNSRS  
60 SNSDDPRLSPPTSSSDTAINSYDAAATATAVAAAAVPVPQYESIELDPAAFFAAANSDLMESSAQ  
GDGGGGEQVPTTENKLVLDLEASSENT

# SEQ ID NO:19: MN1 cDNA

ATGGCAGATGCTAGTTCAAGGACTGACACATCGATTGTTGTAGACAACGACGACAAAAACCA  
 CCAGTTAGAAAACGGACATAGTGGTGCAGTCATGGCTTCTAACTCTTCAGATAGATCTGACAG  
 5 ATCTGACAAACTTATGGACCAAAGACAATGCGGCGGCTTGCTCAAAATCGTGAGGCAGCAA  
 GAAAAAGTCGGCTGAGGAAAAAGGCATATGTGCAACAAGTAGAGAGCAGTAAGCTGAAGCT  
 TGCACAGCTAGAGCAGGAACCTTCAGAAAGCTCGTCAGCAGGGAATCTTCATCTCTAGCTCTGG  
 AGACCAGACCCATGCCATGAGTGGAATGGGGCATTGACTTTTGAAGTACACTAGAT  
 GGCTCGAGGAGCAAAATAAGCAGATAAATGAGTTGAGGACAGCAGTGAATGCTCATGCAAGT  
 10 GACAGTGACCTTCGTCTTATTGTTGATGGCATAATGGCGCATTATGACGAGGTATTCAAGGTT  
 AAGGGTGTAGCTGCAAAGGCCGATGTGTTTCATATACTTTCAGGCATGTGGAAGACACCCGCA  
 GAAAGATGCTTCCTGTGGCTTGGTGGTTTCCGTCCATCTGAGCTTCTAAAGCTCCTAGCAAATC  
 ACCTCGAACCTTTAACCGAGCAGCAGTTGCTGGGATTAAACAACCTCCAGGAATCTTCTCAGC  
 AGGCGGAGGATGCACTTTCACAAGGTATGGAAGCACTGCAGCAATCTCTGGCAGATACTTTG  
 15 GCTGGATCTCTCGCTTCATCAGGGTCTTCTGGGAATGTGGCGAACTACATGGGTCAGATGGCA  
 ATGGCCATGGGTAAACTAGGAACGCTCGAGAATTTCTTTGCCAGGCGGACAACCTGCGACA  
 GCAGACATTGCATCAAATGCAACGAATTCTGACGATCCGGCAAGCCTCGCGTGCTCTTCTTGC  
 CATAACGATTACTTTTCACGCTTGCCTGCTTTGAGTTCGCTGTGGCTTGCTAGGCCACGGGAG  
 TAA

20

## SEQ ID NO:20 MN1 polypeptide

MADASSRTDTSIVVDNDDKNHQLENGHSGAVMASNSSDRSDRDKLMDQKTMRRLAQNREAAR  
 KSRLRKKAYVQQLLESSKLKLAQLEQELQKARQQGIFISSGDQTHAMSGNGALTFDLEYTRWLEE  
 25 QNKQINELRTAVNAHASDSLRLIVDGMMAHYDEVFKVKGVAADVFHILSGMWKTPAERCFL  
 WLGGFRPSELLKLLANHLEPLTEQQLLGLNNLQESSQQAEDALSQGMEALQQSLADTLAGSLASS  
 GSSGNVANYMGQMAMAMGKLTLENFLCQADNLRQQLHQMQRILTIRQASRALLAIHDYFSRL  
 RALSSLWLARPRE

WHAT IS CLAIMED IS:

1. An isolated nucleic acid construct comprising a polynucleotide sequence that:

1) is at least 50% identical to a polynucleotide selected from the group comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, and SEQ ID NO:17; or

2) encodes a polypeptide selected from the group comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, and SEQ ID NO:18.

2. The construct of claim 1, wherein the polynucleotide is from a rice plant.

3. The construct of claim 1, wherein the polynucleotide is at least 50% identical to SEQ ID NO:1.

4. The construct of claim 1, wherein the polynucleotide is at least 50% identical to SEQ ID NO:3.

5. The construct of claim 1, wherein the polynucleotide is at least 50% identical to SEQ ID NO:5.

6. The construct of claim 1, wherein the polynucleotide is at least 50% identical to SEQ ID NO:7.

7. The construct of claim 1, wherein the polynucleotide is at least 50% identical to SEQ ID NO:9.

8. The construct of claim 1, wherein the polynucleotide is at least 50% identical to SEQ ID NO:11.

9. The construct of claim 1, wherein the polynucleotide is at least 50% identical to SEQ ID NO:13.

10. The construct of claim 1, wherein the polynucleotide is at least 50% identical to SEQ ID NO:15.

11. The construct of claim 1, wherein the polynucleotide is at least 50% identical to SEQ ID NO:17.

12. The construct of claim 1, wherein the polynucleotide is SEQ ID NO:1.

13. The construct of claim 1, wherein the polynucleotide is SEQ ID NO:3.

14. The construct of claim 1, wherein the polynucleotide is SEQ ID NO:5.

15. The construct of claim 1, wherein the polynucleotide is SEQ ID NO:7.

16. The construct of claim 1, wherein the polynucleotide is SEQ ID NO:9.

17. The construct of claim 1, wherein the polynucleotide is SEQ ID NO:11.

18. The construct of claim 1, wherein the polynucleotide is SEQ ID NO:13.

19. The construct of claim 1, wherein the polynucleotide is SEQ ID NO:15.

20. The construct of claim 1, wherein the polynucleotide is SEQ ID NO:17.

21. The construct of claim 1, wherein the polynucleotide encodes SEQ ID:2.

22. The construct of claim 1, wherein the polynucleotide encodes SEQ ID:4.

23. The construct of claim 1, wherein the polynucleotide encodes SEQ ID:6.

24. The construct of claim 1, wherein the polynucleotide encodes SEQ ID:8.

25. The construct of claim 1, wherein the polynucleotide encodes SEQ ID:10.

5 26. The construct of claim 1, wherein the polynucleotide encodes SEQ ID:12.

27. The construct of claim 1, wherein the polynucleotide encodes SEQ ID:14.

10 28. The construct of claim 1, wherein the polynucleotide encodes SEQ ID:16.

29. The construct of claim 1, wherein the polynucleotide encodes SEQ ID:18.

30. The construct of claim 1, further comprising a promoter operably linked to the polynucleotide sequence.

15 31. A transgenic plant comprising a recombinant expression cassette comprising a plant promoter operably linked to a polynucleotide sequence that encodes a polypeptide wherein the polynucleotide:

20 1) is at least 50% identical to a polynucleotide selected from the group comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, and SEQ ID NO:17; or

2) encodes a polypeptide selected from the group comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, and SEQ ID NO:18.

32. The transgenic plant of claim 31, wherein the plant is rice.

25 33. The transgenic plant of claim 31, wherein the polynucleotide is at least 50% identical to SEQ ID NO:1.



34. The transgenic plant of claim 31, wherein the polynucleotide is at least 50% identical to SEQ ID NO:3.

35. The transgenic plant of claim 31, wherein the polynucleotide is at least 50% identical to SEQ ID NO:5.

5 36. The transgenic plant of claim 31, wherein the polynucleotide is at least 50% identical to SEQ ID NO:7.

37. The transgenic plant of claim 31, wherein the polynucleotide is at least 50% identical to SEQ ID NO:9.

10 38. The transgenic plant of claim 31, wherein the polynucleotide is at least 50% identical to SEQ ID NO:11.

39. The transgenic plant of claim 31, wherein the polynucleotide is at least 50% identical to SEQ ID NO:13.

40. The transgenic plant of claim 31, wherein the polynucleotide is at least 50% identical to SEQ ID NO:15.

15 41. The transgenic plant of claim 31, wherein the polynucleotide is at least 50% identical to SEQ ID NO:17.

42. The transgenic plant of claim 31, wherein the polynucleotide is SEQ ID NO:1.

20 43. The transgenic plant of claim 31, wherein the polynucleotide is SEQ ID NO:3.

44. The transgenic plant of claim 31, wherein the polynucleotide is SEQ ID NO:5.

45. The transgenic plant of claim 31, wherein the polynucleotide is SEQ ID NO:7.

25 46. The transgenic plant of claim 31, wherein the polynucleotide is SEQ ID NO:9.

47. The transgenic plant of claim 31, wherein the polynucleotide is  
SEQ ID NO:11.

48. The transgenic plant of claim 31, wherein the polynucleotide is  
SEQ ID NO:13.

5 49. The transgenic plant of claim 31, wherein the polynucleotide is  
SEQ ID NO:15.

50. The transgenic plant of claim 31, wherein the polynucleotide is  
SEQ ID NO:17.

10 51. The transgenic plant of claim 31, wherein the polynucleotide  
encodes SEQ ID:2.

52. The transgenic plant of claim 31, wherein the polynucleotide  
encodes SEQ ID:4.

53. The transgenic plant of claim 31, wherein the polynucleotide  
encodes SEQ ID:6.

15 54. The transgenic plant of claim 31, wherein the polynucleotide  
encodes SEQ ID:8.

55. The transgenic plant of claim 31, wherein the polynucleotide  
encodes SEQ ID:10.

20 56. The transgenic plant of claim 31, wherein the polynucleotide  
encodes SEQ ID:12.

57. The transgenic plant of claim 31, wherein the polynucleotide  
encodes SEQ ID:14.

58. The transgenic plant of claim 31, wherein the polynucleotide  
encodes SEQ ID:16.

25 59. The transgenic plant of claim 31, wherein the polynucleotide  
encodes SEQ ID:18.

60. A method of enhancing resistance to pathogens in a plant, the method comprising

1) introducing into the plant a recombinant expression cassette comprising a plant promoter operably linked to a polynucleotide sequence, wherein the

5 polynucleotide sequence:

a) is at least 50% identical to a polynucleotide selected from the group comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, and SEQ ID NO:17; or

10 b) encodes a polypeptide selected from the group comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, and SEQ ID NO:18; and

2) selecting a plant with enhanced resistance.

61. The method of claim 60, wherein the polypeptide comprises SEQ ID NO:2.

15 62. The method of claim 60, wherein the polypeptide comprises SEQ ID NO:4.

63. The method of claim 60, wherein the polypeptide comprises SEQ ID NO:6.

20 64. The method of claim 60, wherein the polypeptide comprises SEQ ID NO:8.

65. The method of claim 60, wherein the polypeptide comprises SEQ ID NO:10.

66. The method of claim 60, wherein the polypeptide comprises SEQ ID NO:12.

25 67. The method of claim 60, wherein the polypeptide comprises SEQ ID NO:14.

68. The method of claim 60, wherein the polypeptide comprises SEQ  
ID NO:16.

69. The method of claim 60, wherein the polypeptide comprises SEQ  
ID NO:18.

## ABSTRACT OF THE DISCLOSURE

The present invention provides the identification and characterization of the rice polypeptide sequence, PNI. The present invention also provides the first identification and characterization of the rice polypeptide sequences that interact with the polypeptides PNI and MN1. The present invention also provides the polynucleotide sequences encoding such polypeptides as well as methods of enhancing resistance to pathogens by introducing the polynucleotides into plants.

SF 209078 v1

### DECLARATION

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **PROTEINS THAT REGULATE SYSTEMIC ACQUIRED RESISTANCE IN PLANTS** the specification of which \_\_\_ is attached hereto or X was filed on April 19, 1999 as Application No. \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

#### Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status

Full Name of Inventor 1:	Last Name: <b>CHERN</b>	First Name: <b>MAW SHENQ</b>	Middle Name or Initial:	
Residence & Citizenship:	City:	State/Foreign Country:	Country of Citizenship:	
Post Office Address:	Post Office Address:	City:	State/Country:	Postal Code:
Full Name of Inventor 2:	Last Name: <b>RONALD</b>	First Name: <b>PAMELA</b>	Middle Name or Initial:	
Residence & Citizenship:	City:	State/Foreign Country:	Country of Citizenship:	
Post Office Address:	Post Office Address:	City:	State/Country:	Postal Code:

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1	Signature of Inventor 2	Signature of Inventor 3
<hr/> MAW SHENQ CHERN	<hr/> PAMELA RONALD	<hr/>
Date	Date	Date

SF 213203 v1